ALTAltimmune, Inc.

Healthcare
$2.60-34% 1Y

The financials

Altimmune, Inc. by the numbers

For the full year FY2025, revenue was $41K (+105% year on year) and net income −$88M. The next results filing is expected around Nov 5, 2026, the same week as a year ago.

Altimmune, Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Revenuen/a$5Kn/a
Operating income−$26M−$23Mn/a
Net income−$23M−$22Mn/a
Diluted EPS−$0.12−$0.27n/a

Biotechnology

Ranks #102 of 196 by RyuScore

Compare peers
PROK+5.0%
PROKIDNEY CORP.
PBYI+1.6%
PUMA BIOTECHNOLOGY, INC.
DRUG+0.58%
BRIGHT MINDS BIOSCIENCES INC.
EPRX-2.7%
EUPRAXIA PHARMACEUTICALS INC.
CTNM+3.7%
Contineum Therapeutics, Inc.
OCS+1.3%
Oculis Holding AG